Strategic Partners (DB:1TB0) - Hisse Senedi Fiyatı, Haberler ve Analizler

1TB0 Stoklara Genel Bakış

Strategic Partners A/S'nin önemli bir faaliyeti bulunmamaktadır.

1TB0 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 42.7% oranında arttı

Risk Analizi

Anlamlı bir piyasa değeri yok ( €40M )

Geliri 1 milyon ABD dolarından az ( DKK0 )

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl sulandırıldı

Strategic Partners A/S Rakipler

4SC

DB:VSC

€61.5m

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€24.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Strategic Partners
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	DKK 137.50
52 Haftanın En Yüksek Seviyesi	DKK 181.50
52 Haftanın En Düşük Seviyesi	DKK 89.50
Beta	0.079
11 Aylık Değişim	-7.41%
3 Aylık Değişim	27.31%
1 Yıllık Değişim	28.75%
33 Yıllık Değişim	-96.14%
5 Yıllık Değişim	-97.94%
Halka arzdan bu yana değişim	-97.76%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	1TB0	DE Biotechs	DE Pazar
7D	-7.4%	-3.1%	-1.0%
1Y	28.7%	-15.2%	16.1%

Getiri vs. Endüstri: 1TB0 geçen yıl % -15.2 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: 1TB0 geçen yıl % 16.1 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 1TB0's price volatile compared to industry and market?
1TB0 volatility
1TB0 Average Weekly Movement	12.3%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

İstikrarlı Hisse Senedi Fiyatı: 1TB0 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 1TB0 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	1	Jakob Bendtsen	www.strategic-partners.dk

Strategic Partners A/S'nin önemli bir faaliyeti bulunmamaktadır. Daha önce, nörodejeneratif nadir hastalıkların tedavisi için tedavilerin geliştirilmesiyle uğraşıyordu. Şirket daha önce Orphazyme A/S olarak biliniyordu ve Ekim 2024'te adını Strategic Partners A/S olarak değiştirdi.

Strategic Partners A/S Temel Bilgiler Özeti

Strategic Partners'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
1TB0 temel i̇stati̇sti̇kler
Piyasa değeri	€5.30m
Kazançlar(TTM)	-€1.53m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-3.5x

F/K Oranı

1TB0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
1TB0 gelir tablosu (TTM)
Gelir	DKK 0
Gelir Maliyeti	DKK 0
Brüt Kâr	DKK 0
Diğer Giderler	DKK 11.42m
Kazançlar	-DKK 11.42m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-273.69
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

1TB0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

1TB0 Stoklara Genel Bakış

Ödüller

Risk Analizi

Strategic Partners A/S Rakipler

DB:VSC

€61.5m

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€24.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Financial data availability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Recent updates

New major risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Financial data availability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022

KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.

Orphazyme A/S Announces Executive Changes

Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S, Annual General Meeting, May 21, 2022

Forecast to breakeven in 2024

Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union

Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors

Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States

Orphazyme to Present Additional Data on Arimoclomol’s Mechanism of Action During 2022 Annual Worldsymposium™

Orphazyme A/S Announces CEO Changes

Orphazyme A/S Revises Earnings Guidance for the Year 2021

Forecast to breakeven in 2024

Orphazyme A/S Maintains its Outlook for the Full Year 2021

Orphazyme A/S Announces Publication of Results from Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C in the Journal of Inherited Metabolic Disease

Independent Director Martijn Kleijwegt has left the company

Independent Director Remi P. Droller has left the company

Independent Director Anders Hedegaard has left the company

CytRx Corporation Announces 24-Month Interim Results of an Open-Label Extension Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Orphazyme Provides Earnings Guidance for the Year of 2021

Orphazyme A/S Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Independent Director has left the company

Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021

Orphazyme A/S to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual Worldsymposium™

New 90-day high: €10.56

CytRx Corporation Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Announces the U.S. Food and Drug Administration Has Extended the Review Period of the New Drug Application

New 90-day low: €7.41

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, Mar 25, 2021

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

Orphazyme A/S Submits European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

New 90-day low: €8.67

Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.

Orphazyme A/S Provides Update on Previously Announced Global Offering

New 90-day low: €9.92

Orphazyme A/S Elects Carrolee Barlow as Board of Director

New 90-day low - €11.52